According to data recently released by CMS actuaries, spending on health care in the U.S. jumped to $5.7 trillion in 2025, the third consecutive year in which spending growth exceeded 7%. This spike underscores the escalating financial burden on the nation’s health system, with pricey medications such as GLP-1s—used to treat obesity—emerging as a significant contributor to the surge.
The data highlights a trend that is bound to be of major concern to health insurance providers, including Astiva Health and other carriers. As costs climb, insurers face pressure to adjust premiums and coverage policies, potentially impacting millions of Americans. The implications extend beyond insurers to employers, government programs like Medicare and Medicaid, and individual consumers who may see higher out-of-pocket expenses.
GLP-1 receptor agonists, originally developed for diabetes management, have gained widespread use for weight loss, driving up pharmaceutical spending. Their high cost per patient amplifies overall health care expenditure, a factor that policymakers and industry stakeholders are closely monitoring. The BioMedWire report notes that these medications represent just one facet of a broader cost escalation that includes hospital services, physician care, and administrative expenses.
The sustained growth rate above 7% for three years signals a structural shift rather than a temporary anomaly. Analysts point to an aging population, advances in medical technology, and increased utilization of health services as underlying drivers. However, the prominence of GLP-1s in the latest data suggests that innovative but expensive therapies will continue to shape spending patterns.
For health insurers, managing this trend requires balancing actuarial soundness with affordability for policyholders. Companies like Astiva Health are likely to explore strategies such as formulary management, value-based care arrangements, and wellness programs to mitigate cost increases. The broader economic impact includes potential effects on inflation, wage growth, and government budgets, as health care consumes a growing share of GDP.
As the U.S. health care system navigates this trajectory, stakeholders must confront tough questions about sustainability and access. The CMS data serves as a critical benchmark for evaluating policy interventions and market dynamics. With spending showing no signs of deceleration, the urgency for innovative solutions has never been greater.
